Vaccine comprising natural killer cells loaded with ligands of natural killer T cells and cancer antigens

An immunotherapeutic vaccine comprising natural killer cells loaded with natural killer T cell ligands and cancer antigens,

• wherein the natural killer T cell ligands are alpha-galactosylceramide, and
• wherein the cancer antigens are selected from the group consisting of gp 100 (glycoprotein 100, melanoma antigen gene (MAGE), human papilloma virus (HPV) E6/E7, tyrosinase, tyrosinase-related protein-1 (TRP-1), tyrosinase-related protein-2 (TRP-2), murinoglobulin 1 (MUC-1), carcinoembryonic antigen (CEA), p53, α-fetoprotein, Her-2/neu, proteinase 3, Wilms' Tumor 1 (WT-1), Prostatic Acid Phosphatase (PAP), Prostate-Specific Antigen (PSA), Prostate-Specific Membrane Antigen (PSMA), Carbonic Anhydrase IX (G250), B Melanoma Antigen (BAGE), Cancer/testis G Antigen (GAGE), New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1), Melanoma Antigen Recognized by T cells 1 (MART-1), Melanocortin 1 Receptor (MC1R), Ig (Immunoglobulin) Idiotype, CDK4 (cyclin-dependent kinase 4), caspase-8, Beta-Catenin (β-catenin), Cancer Immuno-Antigen (CIA), Breakpoint Cluster Region-Abelson (BCR/ABL), Epstein-Barr Virus Latent Membrane Protein 2A (EBV LMP2a), Hepatitis C Virus (HCV), Human Herpesvirus 8 (HHV-8), 5T4 Oncofetal Antigen (5T4), and tumor-specific mutation-derived neoantigens.